Network Pharmacology and Experimental Validation of a Securidaca inappendiculata Xanthone Fraction Targeting Rheumatoid Arthritis via the PI3K/AKT/mTOR/HIF-1α/GSK-3β Axis.
- DOI
- 10.2174/0115734099490013260821075759
- Published
- 2026 Aug 28
- Container
- Current computer-aided drug design
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2174/0115734099490013260821075759,
title = {Network Pharmacology and Experimental Validation of a Securidaca inappendiculata Xanthone Fraction Targeting Rheumatoid Arthritis via the PI3K/AKT/mTOR/HIF-1α/GSK-3β Axis.},
author = {Chen X and Fan B and Wang T and Zhou Y and Ding W and Han Y and Wang G and Zhou Y},
year = {2026},
journal = {Current computer-aided drug design},
doi = {10.2174/0115734099490013260821075759},
url = {https://doi.org/10.2174/0115734099490013260821075759}
}RIS
TY - JOUR TI - Network Pharmacology and Experimental Validation of a Securidaca inappendiculata Xanthone Fraction Targeting Rheumatoid Arthritis via the PI3K/AKT/mTOR/HIF-1α/GSK-3β Axis. AU - Chen X AU - Fan B AU - Wang T AU - Zhou Y AU - Ding W AU - Han Y AU - Wang G AU - Zhou Y PY - 2026 JO - Current computer-aided drug design DO - 10.2174/0115734099490013260821075759 UR - https://doi.org/10.2174/0115734099490013260821075759 ER -
APA
X, C., B, F., T, W., Y, Z., W, D., Y, H., G, W., & Y, Z. (2026). Network Pharmacology and Experimental Validation of a Securidaca inappendiculata Xanthone Fraction Targeting Rheumatoid Arthritis via the PI3K/AKT/mTOR/HIF-1α/GSK-3β Axis.. Current computer-aided drug design. https://doi.org/10.2174/0115734099490013260821075759
Source records
- pubmed · retrieved 2026-09-26T09:02:15.585Z